Rice Market
Description
Rice Market Summary
The global rice market size was estimated at USD 310.53 billion in 2025 and is projected to reach USD 391.82 billion by 2033, growing at a CAGR of 3.0% from 2026 to 2033. Rice is a staple food for more than half of the world’s population and contributes close to one-fifth of total caloric intake worldwide.
According to data from the FAO and national agriculture agencies, global rice consumption crossed 510 million metric tons in 2024, driven primarily by population growth in Asia and Africa, rising urbanisation, and the affordability of rice compared with other staple grains. Governments across developing economies continue to prioritise rice production and procurement as part of food security programs, which further supports sustained market expansion.
While rice remains a basic staple, consumers are increasingly demanding higher-quality, healthier, and more differentiated rice products. There is growing interest in brown rice, parboiled rice, organic rice, and low-glycaemic-index varieties, particularly among urban consumers who associate these products with better digestion, weight management, and diabetes control. Recent surveys state that rice’s gluten-free nature and versatility have strengthened its position among health-conscious consumers and those with dietary restrictions. At the same time, busy lifestyles are boosting demand for easy-to-cook, pre-washed, and ready-to-heat rice formats.
In Mexico, rice remains an important staple in the national diet, though its consumption patterns and market dynamics differ from those in high-rice consumption countries in Asia. Rice is considered a basic cereal in Mexican diets and figures in many traditional meals such as arroz a la tumbada, morisqueta, and arroz rojo where it complements beans, stews, and other proteins in everyday family cooking.
Cultural diversity plays a major role in sustaining and expanding rice consumption across regions. In South Asia, rice is deeply embedded in everyday meals as well as religious and ceremonial occasions, with varieties such as basmati and sona masuri dominating household consumption. In East Asia, short-grain and medium-grain rice are integral to traditional meals and food rituals, particularly in countries such as Japan and South Korea. Southeast Asian cuisines rely heavily on jasmine and sticky rice, while in the Middle East and parts of Africa, rice is central to communal dishes and festive meals. Beyond traditional consumption, the globalization of food culture has increased exposure to international rice-based cuisines such as sushi, risotto, paella, biryani, rice bowls, and fried rice, encouraging consumers to experiment with new cooking styles and rice varieties.
In addition, consumers are showing rising interest in aromatic rice varieties such as basmati and jasmine due to their fragrance and texture, while flavored and seasoned rice products are gaining traction in urban retail channels. India and China remain the world’s largest rice-consuming countries in 2024, largely due to their population size and cultural dependence on rice as a daily staple. Data from the FAO, USDA, and national agriculture ministries indicate that India and China together account for more than half of global rice consumption, with India consuming well over 100 million metric tons annually. Countries such as Bangladesh, Indonesia, and Vietnam also rank among the top consumers, reflecting both high population reliance on rice and limited substitution with other staples. On a per-capita basis, Southeast Asian countries such as Vietnam and Indonesia continue to record some of the highest rice consumption levels globally, according to government nutrition surveys and agricultural statistics.
Global Rice Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rice market report on the basis of product, distribution channel, and region:
The global rice market size was estimated at USD 310.53 billion in 2025 and is projected to reach USD 391.82 billion by 2033, growing at a CAGR of 3.0% from 2026 to 2033. Rice is a staple food for more than half of the world’s population and contributes close to one-fifth of total caloric intake worldwide.
According to data from the FAO and national agriculture agencies, global rice consumption crossed 510 million metric tons in 2024, driven primarily by population growth in Asia and Africa, rising urbanisation, and the affordability of rice compared with other staple grains. Governments across developing economies continue to prioritise rice production and procurement as part of food security programs, which further supports sustained market expansion.
While rice remains a basic staple, consumers are increasingly demanding higher-quality, healthier, and more differentiated rice products. There is growing interest in brown rice, parboiled rice, organic rice, and low-glycaemic-index varieties, particularly among urban consumers who associate these products with better digestion, weight management, and diabetes control. Recent surveys state that rice’s gluten-free nature and versatility have strengthened its position among health-conscious consumers and those with dietary restrictions. At the same time, busy lifestyles are boosting demand for easy-to-cook, pre-washed, and ready-to-heat rice formats.
In Mexico, rice remains an important staple in the national diet, though its consumption patterns and market dynamics differ from those in high-rice consumption countries in Asia. Rice is considered a basic cereal in Mexican diets and figures in many traditional meals such as arroz a la tumbada, morisqueta, and arroz rojo where it complements beans, stews, and other proteins in everyday family cooking.
Cultural diversity plays a major role in sustaining and expanding rice consumption across regions. In South Asia, rice is deeply embedded in everyday meals as well as religious and ceremonial occasions, with varieties such as basmati and sona masuri dominating household consumption. In East Asia, short-grain and medium-grain rice are integral to traditional meals and food rituals, particularly in countries such as Japan and South Korea. Southeast Asian cuisines rely heavily on jasmine and sticky rice, while in the Middle East and parts of Africa, rice is central to communal dishes and festive meals. Beyond traditional consumption, the globalization of food culture has increased exposure to international rice-based cuisines such as sushi, risotto, paella, biryani, rice bowls, and fried rice, encouraging consumers to experiment with new cooking styles and rice varieties.
In addition, consumers are showing rising interest in aromatic rice varieties such as basmati and jasmine due to their fragrance and texture, while flavored and seasoned rice products are gaining traction in urban retail channels. India and China remain the world’s largest rice-consuming countries in 2024, largely due to their population size and cultural dependence on rice as a daily staple. Data from the FAO, USDA, and national agriculture ministries indicate that India and China together account for more than half of global rice consumption, with India consuming well over 100 million metric tons annually. Countries such as Bangladesh, Indonesia, and Vietnam also rank among the top consumers, reflecting both high population reliance on rice and limited substitution with other staples. On a per-capita basis, Southeast Asian countries such as Vietnam and Indonesia continue to record some of the highest rice consumption levels globally, according to government nutrition surveys and agricultural statistics.
Global Rice Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rice market report on the basis of product, distribution channel, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Long-grain
- Medium-grain
- Short-grain
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Offline
- Online
- Regional Outlook (Revenue, Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- South Korea
- Central & South America
- Brazil
- Middle East & Africa (MEA)
- South Africa
Table of Contents
80 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Brand
- 1.2.3. Serotype
- 1.2.4. Age Group
- 1.2.5. Sales Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Meningococcal Vaccines Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- Chapter 4. Meningococcal Vaccines Market: Type Business Analysis
- 4.1. Type Market Share, 2025 & 2033
- 4.2. Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 4.4. Bivalent
- 4.4.1. Bivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Quadrivalent
- 4.5.1. Quadrivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Others
- 4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Meningococcal Vaccines Market: Brand Business Analysis
- 5.1. Brand Market Share, 2025 & 2033
- 5.2. Brand Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Brand, 2021 to 2033 (USD Million)
- 5.4. Menactra
- 5.4.1. Menactra Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Menveo
- 5.5.1. Menveo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Nimenrix
- 5.6.1. Nimenrix Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Trumenba
- 5.7.1. Trumenba Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.8. Bexsero
- 5.8.1. Bexsero Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.9. Others
- 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Meningococcal Vaccines Market: Serotype Business Analysis
- 6.1. Serotype Market Share, 2025 & 2033
- 6.2. Serotype Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Serotype, 2021 to 2033 (USD Million)
- 6.4. A
- 6.4.1. A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. B
- 6.5.1. B Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. C
- 6.6.1. C Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. W-135
- 6.7.1. W-135 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8. Y
- 6.8.1. Y Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Meningococcal Vaccines Market: Age Group Business Analysis
- 7.1. Age Group Market Share, 2025 & 2033
- 7.2. Age Group Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
- 7.4. Infants (0 to 2 years)
- 7.4.1. Infants (0 to 2 years) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Children and Adults (2 years and above)
- 7.5.1. Children and Adults (2 years and above) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Meningococcal Vaccines Market: Sales Channel Business Analysis
- 8.1. Sales Channel Market Share, 2025 & 2033
- 8.2. Sales Channel Segment Dashboard
- 8.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
- 8.4. Private
- 8.4.1. Private Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Public
- 8.5.1. Public Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 9. Meningococcal Vaccines Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Share Analysis, 2025 & 2033
- 9.2. Regional Market Dashboard
- 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 9.4. North America
- 9.4.1. North America Meningococcal Vaccines Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 9.4.2. U.S.
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Type Disease Prevalence
- 9.4.2.3. Regulatory Framework
- 9.4.2.4. Reimbursement Framework
- 9.4.2.5. U.S. Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.3. Canada
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Type Disease Prevalence
- 9.4.3.3. Regulatory Framework
- 9.4.3.4. Reimbursement Framework
- 9.4.3.5. Canada Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.4. Mexico
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Type Disease Prevalence
- 9.4.4.3. Regulatory Framework
- 9.4.4.4. Reimbursement Framework
- 9.4.4.5. Mexico Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. Europe
- 9.5.1. Europe Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.2. UK
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Type Disease Prevalence
- 9.5.2.3. Regulatory Framework
- 9.5.2.4. Reimbursement Framework
- 9.5.2.5. UK Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.3. Germany
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Type Disease Prevalence
- 9.5.3.3. Regulatory Framework
- 9.5.3.4. Reimbursement Framework
- 9.5.3.5. Germany Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.4. France
- 9.5.4.1. Key Country Dynamics
- 9.5.4.2. Type Disease Prevalence
- 9.5.4.3. Regulatory Framework
- 9.5.4.4. Reimbursement Framework
- 9.5.4.5. France Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.5. Italy
- 9.5.5.1. Key Country Dynamics
- 9.5.5.2. Type Disease Prevalence
- 9.5.5.3. Regulatory Framework
- 9.5.5.4. Reimbursement Framework
- 9.5.5.5. Italy Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.6. Spain
- 9.5.6.1. Key Country Dynamics
- 9.5.6.2. Type Disease Prevalence
- 9.5.6.3. Regulatory Framework
- 9.5.6.4. Reimbursement Framework
- 9.5.6.5. Spain Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.7. Denmark
- 9.5.7.1. Key Country Dynamics
- 9.5.7.2. Type Disease Prevalence
- 9.5.7.3. Regulatory Framework
- 9.5.7.4. Reimbursement Framework
- 9.5.7.5. Denmark Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.8. Sweden
- 9.5.8.1. Key Country Dynamics
- 9.5.8.2. Type Disease Prevalence
- 9.5.8.3. Regulatory Framework
- 9.5.8.4. Reimbursement Framework
- 9.5.8.5. Sweden Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.9. Norway
- 9.5.9.1. Key Country Dynamics
- 9.5.9.2. Type Disease Prevalence
- 9.5.9.3. Regulatory Framework
- 9.5.9.4. Reimbursement Framework
- 9.5.9.5. Norway Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6. Asia Pacific
- 9.6.1. Asia Pacific Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.2. Japan
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Type Disease Prevalence
- 9.6.2.3. Regulatory Framework
- 9.6.2.4. Reimbursement Framework
- 9.6.2.5. Japan Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.3. China
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Type Disease Prevalence
- 9.6.3.3. Regulatory Framework
- 9.6.3.4. Reimbursement Framework
- 9.6.3.5. China Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.4. India
- 9.6.4.1. Key Country Dynamics
- 9.6.4.2. Type Disease Prevalence
- 9.6.4.3. Regulatory Framework
- 9.6.4.4. Reimbursement Framework
- 9.6.4.5. India Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.5. Australia
- 9.6.5.1. Key Country Dynamics
- 9.6.5.2. Type Disease Prevalence
- 9.6.5.3. Regulatory Framework
- 9.6.5.4. Reimbursement Framework
- 9.6.5.5. Australia Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.6. South Korea
- 9.6.6.1. Key Country Dynamics
- 9.6.6.2. Type Disease Prevalence
- 9.6.6.3. Regulatory Framework
- 9.6.6.4. Reimbursement Framework
- 9.6.6.5. South Korea Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.7. Thailand
- 9.6.7.1. Key Country Dynamics
- 9.6.7.2. Type Disease Prevalence
- 9.6.7.3. Regulatory Framework
- 9.6.7.4. Reimbursement Framework
- 9.6.7.5. Thailand Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7. Latin America
- 9.7.1. Latin America Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.2. Brazil
- 9.7.2.1. Key Country Dynamics
- 9.7.2.2. Type Disease Prevalence
- 9.7.2.3. Regulatory Framework
- 9.7.2.4. Reimbursement Framework
- 9.7.2.5. Brazil Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.3. Argentina
- 9.7.3.1. Key Country Dynamics
- 9.7.3.2. Type Disease Prevalence
- 9.7.3.3. Regulatory Framework
- 9.7.3.4. Reimbursement Framework
- 9.7.3.5. Argentina Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.8. Middle East and Africa
- 9.8.1. Middle East and Africa Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.8.2. South Africa
- 9.8.2.1. Key Country Dynamics
- 9.8.2.2. Type Disease Prevalence
- 9.8.2.3. Regulatory Framework
- 9.8.2.4. Reimbursement Framework
- 9.8.2.5. South Africa Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.8.3. Saudi Arabia
- 9.8.3.1. Key Country Dynamics
- 9.8.3.2. Type Disease Prevalence
- 9.8.3.3. Regulatory Framework
- 9.8.3.4. Reimbursement Framework
- 9.8.3.5. Saudi Arabia Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.8.4. UAE
- 9.8.4.1. Key Country Dynamics
- 9.8.4.2. Type Disease Prevalence
- 9.8.4.3. Regulatory Framework
- 9.8.4.4. Reimbursement Framework
- 9.8.4.5. UAE Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.8.5. Kuwait
- 9.8.5.1. Key Country Dynamics
- 9.8.5.2. Type Disease Prevalence
- 9.8.5.3. Regulatory Framework
- 9.8.5.4. Reimbursement Framework
- 9.8.5.5. Kuwait Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 10. Competitive Landscape
- 10.1. Participant Overview
- 10.2. Company Market Position Analysis
- 10.3. Company Categorization
- 10.4. Strategy Mapping
- 10.5. Company Profiles/Listing
- 10.5.1. GlaxoSmithKline
- 10.5.1.1. Overview
- 10.5.1.2. Financial Performance
- 10.5.1.3. Type Benchmarking
- 10.5.1.4. Strategic Initiatives
- 10.5.2. Pfizer
- 10.5.2.1. Overview
- 10.5.2.2. Financial Performance
- 10.5.2.3. Type Benchmarking
- 10.5.2.4. Strategic Initiatives
- 10.5.3. Sanofi
- 10.5.3.1. Overview
- 10.5.3.2. Financial Performance
- 10.5.3.3. Type Benchmarking
- 10.5.3.4. Strategic Initiatives
- 10.5.4. Merck & Co.
- 10.5.4.1. Overview
- 10.5.4.2. Financial Performance
- 10.5.4.3. Type Benchmarking
- 10.5.4.4. Strategic Initiatives
- 10.5.5. Novartis
- 10.5.5.1. Overview
- 10.5.5.2. Financial Performance
- 10.5.5.3. Type Benchmarking
- 10.5.5.4. Strategic Initiatives
- 10.5.6. Serum Institute of India
- 10.5.6.1. Overview
- 10.5.6.2. Financial Performance
- 10.5.6.3. Type Benchmarking
- 10.5.6.4. Strategic Initiatives
- 10.5.7. Walvax Biotechnology
- 10.5.7.1. Overview
- 10.5.7.2. Financial Performance
- 10.5.7.3. Type Benchmarking
- 10.5.7.4. Strategic Initiatives
- 10.5.8. Baxter International
- 10.5.8.1. Overview
- 10.5.8.2. Financial Performance
- 10.5.8.3. Type Benchmarking
- 10.5.8.4. Strategic Initiatives
- 10.5.9. Bio-Med Pvt. Ltd.
- 10.5.9.1. Overview
- 10.5.9.2. Financial Performance
- 10.5.9.3. Type Benchmarking
- 10.5.9.4. Strategic Initiatives
- 10.5.10. Incepta Vaccine Ltd
- 10.5.10.1. Overview
- 10.5.10.2. Financial Performance
- 10.5.10.3. Type Benchmarking
- 10.5.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


